← brief for 2026-09-11 · Slowing decline

The SGLT2i Treatment Gap in UK Primary Care: A Cross-Sectional RWE Study of Prescribing in Clinical Practice.

Article C Peer reviewed Observational

Key takeaways

This UK study looked at family doctor records to count people who qualify for SGLT2 inhibitors but are not taking them. These are pills that protect the kidneys and heart in type 2 diabetes, chronic kidney disease, and heart failure. It found that use in UK primary care falls well short of what guidelines recommend, leaving a large untreated group. This is a snapshot of prescribing, not a test of the drugs, so it shows a gap in care rather than proving what causes it.

Who did this work

Stefanska C · Chung R · Ramjaun S · Jin D · Doherty C · McCafferty K · Seidu S

Source

Article · PubMed, the drug frontier · 2026 Sep 10
https://pubmed.ncbi.nlm.nih.gov/42723263/